ClinicalTrials.gg
WithdrawnNCT07683572Updated Nov 5, 2026

Device Validation of Augmented-Reality ICG Fluorescence Imaging for Sentinel Lymph Node Detection in Breast Cancer

An observational study in Breast Cancer, Breast Neoplasms and Sentinel Lymph Node, sponsored by Ss. Cyril and Methodius University of Skopje. Withdrawn at 1 site in North Macedonia. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by Ss. Cyril and Methodius University of Skopje · Observational

How we know

Why this study was withdrawn
The responsible party decided not to initiate this separate observational device-validation study. No participants were enrolled. The planned AR/VR second-look research is being pursued under NCT07696754.
Updated Nov 5, 2026Now WithdrawnEnrollment updatedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
0
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Breast Neoplasms with a site in North Macedonia — 2 open to participants now, 3 under way, 1 of them phase 3. Breast Neoplasms · North Macedonia.

Started
2026
with 1 other
Observational
2 of 11
1 open now
Registered
10th of 11
by date
Lead sponsor
2 of 11
Ss. Cyril and Methodius University of Skopje

Among the 11 studies in Breast Neoplasms with a site in North Macedonia, this one is one of 2 that started in 2026, is one of 2 observational ones, and was the 10th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

2 of the 11 studies in Breast Neoplasms with a site in North Macedonia are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in North Macedonia have not opened yet or have stopped. Only those recruiting at a site in North Macedonia →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Breast Neoplasms with a site in North Macedonia, or all of them as a file.
02

Study summary

This study evaluates how accurately augmented-reality goggles with indocyanine green (ICG) near-infrared fluorescence can identify sentinel (first-draining) lymph nodes during breast cancer surgery. The goggles and ICG signal are used to mark candidate sentinel nodes, and an additional observer may record near-infrared images during the operation for device-performance assessment. These imaging findings do not change the surgical procedure. The candidate nodes and all removed tissue are examined by histopathology, which serves as the reference standard. Two hundred patients undergoing breast cancer surgery will take part. The study measures how well the goggle-based imaging detects nodes that contain cancer, compared with final pathology.

Read the detailed description

This is a prospective observational device-validation study in patients undergoing breast cancer surgery with axillary evaluation. Augmented-reality goggle-based near-infrared fluorescence imaging with ICG is used to visualize and mark candidate sentinel lymph nodes. Intraoperative near-infrared imaging may be performed by an observer who is not the operating surgeon, solely to assess device performance; observer findings are not communicated to the operating surgeon before wound closure and do not influence the operation. All marked nodes and removed tissue undergo histopathology, which serves as the blinded reference standard. Device performance is assessed on consecutive eligible patients within defined enrollment windows; for each near-infrared imaging device, sensitivity, specificity, positive and negative predictive value, and node-level ROC analysis are estimated against final histopathology, with confidence intervals accounting for clustering of nodes within patients. The study is non-interventional: the imaging does not alter surgical management.

03

Conditions studied

  • Breast Cancer
  • Breast Neoplasms
  • Sentinel Lymph Node
  • Lymphatic Metastasis

Keywords

  • indocyanine green
  • near-infrared fluorescence
  • augmented reality
  • sentinel lymph node biopsy
  • diagnostic accuracy
  • medical device validation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with histologically proven breast cancer undergoing surgery with axillary lymph node evaluation at the participating center, enrolled consecutively.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • proven breast cancer
  • Age 18 years or older
  • Undergoing breast cancer surgery with sentinel lymph node evaluation and/or axillary lymph node dissection
  • Provides written

Exclusion criteria

Exclusion Criteria:

  • Pregnancy
  • chemotherapy
  • Prior breast surgery
  • Iodine or seafood allergy
  • Indocyanine green (ICG) allergy
  • Declines or is unable to provide
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
0 participants (actual)
Patient registry
No

Groups and cohorts

  • Breast cancer patients undergoing surgery with AR-ICG node imaging

    Patients undergoing breast cancer surgery in whom AR-ICG goggle-based near-infrared imaging is used to mark candidate sentinel nodes, with optional observer near-infrared imaging for device-performance assessment; histopathology is the reference standard.

    Device: AR-ICG near-infrared fluorescence imaging

Interventions

  • DeviceAR-ICG near-infrared fluorescence imaging

    Augmented-reality goggle-based near-infrared fluorescence imaging with indocyanine green (ICG), used to visualize and mark candidate sentinel lymph nodes during breast cancer surgery. Intraoperative near-infrared imaging may also be recorded by an observer for device-performance assessment. Imaging does not alter surgical management; histopathology serves as the reference standard.

06

What researchers measure

Primary outcomes

  1. Node-level diagnostic accuracy of AR-ICG fluorescence imaging versus histopathology

    Sensitivity, specificity, positive and negative predictive value, and area under the ROC curve for goggle-based near-infrared fluorescence detection of tumor-positive lymph nodes, using final histopathology as the reference standard, with confidence intervals accounting for clustering of nodes within patients.

    Time frame: From surgery to final histopathology (up to ~2 weeks after surgery)

Secondary outcomes

  1. Patient-level sentinel-node detection rate

    Proportion of patients in whom at least one sentinel lymph node is identified by AR-ICG near-infrared fluorescence imaging.

    Time frame: Final histopathology (up to approximately 2 weeks after surgery)

  2. Concordance of device-marked nodes with histopathology

    Agreement between lymph nodes marked by AR-ICG fluorescence imaging and nodal status confirmed on final histopathology.

    Time frame: Final histopathology (up to approximately 2 weeks after surgery)

  3. Per-device diagnostic performance across near-infrared imaging systems

    Sensitivity, specificity, positive predictive value, negative predictive value, and area under the ROC curve estimated separately for each near-infrared imaging device evaluated, using final histopathology as the reference standard, on consecutive eligible patients within defined enrollment windows.

    Time frame: Through study completion (up to approximately 24 months)

  4. False-negative rate of AR-ICG fluorescence node detection

    Proportion of pathology-confirmed tumor-positive lymph nodes not identified as fluorescent by AR-ICG imaging.

    Time frame: Final histopathology (up to approximately 2 weeks after surgery)

  5. Number of candidate sentinel nodes identified per patient

    Number of candidate sentinel lymph nodes marked by AR-ICG fluorescence imaging per patient (count).

    Time frame: Intraoperative (day of surgery)

07

Study locations

1 site
08

References and documents

Publications

  • Giuliano AE, Ballman KV, McCall L, Beitsch PD, Brennan MB, Kelemen PR, Ollila DW, Hansen NM, Whitworth PW, Blumencranz PW, Leitch AM, Saha S, Hunt KK, Morrow M. Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial. JAMA. 2017 Sep 12;318(10):918-926. doi: 10.1001/jama.2017.11470. PubMed 28898379 ↗
  • Xiong X, Zheng LW, Ding Y, Chen YF, Cai YW, Wang LP, Huang L, Liu CC, Shao ZM, Yu KD. Breast cancer: pathogenesis and treatments. Signal Transduct Target Ther. 2025 Feb 19;10(1):49. doi: 10.1038/s41392-024-02108-4. PubMed 39966355 ↗
  • Donker M, van Tienhoven G, Straver ME, Meijnen P, van de Velde CJ, Mansel RE, Cataliotti L, Westenberg AH, Klinkenbijl JH, Orzalesi L, Bouma WH, van der Mijle HC, Nieuwenhuijzen GA, Veltkamp SC, Slaets L, Duez NJ, de Graaf PW, van Dalen T, Marinelli A, Rijna H, Snoj M, Bundred NJ, Merkus JW, Belkacemi Y, Petignat P, Schinagl DA, Coens C, Messina CG, Bogaerts J, Rutgers EJ. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol. 2014 Nov;15(12):1303-10. doi: 10.1016/S1470-2045(14)70460-7. Epub 2014 Oct 15. PubMed 25439688 ↗
  • de Boniface J, Filtenborg Tvedskov T, Ryden L, Szulkin R, Reimer T, Kuhn T, Kontos M, Gentilini OD, Olofsson Bagge R, Sund M, Lundstedt D, Appelgren M, Ahlgren J, Norenstedt S, Celebioglu F, Sackey H, Scheel Andersen I, Hoyer U, Nyman PF, Vikhe Patil E, Wieslander E, Dahl Nissen H, Alkner S, Andersson Y, Offersen BV, Bergkvist L, Frisell J, Christiansen P; SENOMAC Trialists' Group; SENOMAC Trialists' Group. Omitting Axillary Dissection in Breast Cancer with Sentinel-Node Metastases. N Engl J Med. 2024 Apr 4;390(13):1163-1175. doi: 10.1056/NEJMoa2313487. PubMed 38598571 ↗

Individual participant data

Plan to share: No — This is a single-center observational device-validation study. Individual participant data are not planned to be shared. De-identified data may be made available from the principal investigator on reasonable request, subject to institutional approval.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jul 2026; primary completion for Jul 2028, 24 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 28, 2026
First posted
Jul 6, 2026
StartEst.
Jul 1, 2026
Primary completionEst.
Jul 1, 2028
CompletionEst.
Dec 31, 2028
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Withdrawn The responsible party decided not to initiate this separate observational device-validation study. No participants were enrolled. The planned AR/VR second-look research is being pursued under NCT07696754.
changed Nov 5, 2026
Enrollment
200 (estimated)→0 (actual)
Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    Not yet recruiting→Withdrawn
    Why stopped The responsible party decided not to initiate this separate observational device-validation study. No participants were enrolled. The planned AR/VR second-look research is being pursued under NCT07696754.
    Enrollment 200 (estimated)→0 (actual)
    + 2 other changes: verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07683572
Lead sponsor
Ss. Cyril and Methodius University of Skopje
Responsible party
Borislav Kondov (Professor / Principal Investigator, Ss. Cyril and Methodius University of Skopje) — Principal investigator
First posted
Jul 6, 2026
Start date
Jul 1, 2026 (estimated)
Primary completion
Jul 1, 2028 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Nov 5, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion